Inflammatory bowel disease induced by bimekizumab

Dominika Wietrzykowska-Grishanovich; Maciej Pleskacz; Radosław Kempiński

doi:10.5114/pg.2022.116374

eISSN: 1897-4317
ISSN: 1895-5770

Gastroenterology Review/Przegląd Gastroenterologiczny

Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

2/2022
vol. 17

Send email

Copy url:

abstract:

Letter to the Editor

Inflammatory bowel disease induced by bimekizumab

Dominika Wietrzykowska-Grishanovich

¹

,

Maciej Pleskacz

¹

,

Radosław Kempiński

²

Department of Gastroenterology and Hepatology, University Hospital, Wroclaw, Poland
Department of Gastroenterology and Hepatology, University Hospital, Wroclaw Medical University, Wroclaw, Poland

Gastroenterology Rev 2022; 17 (2): 175–176

DOI: https://doi.org/10.5114/pg.2022.116374

Online publish date: 2022/05/19

View full text Get citation

PlumX metrics:

Inflammatory bowel disease (IBD) is a chronic condition of the gastrointestinal tract, with a complex aetiopathogenesis in which genetic, immunological, and environmental factors are being discussed. The development of knowledge about molecular processes and the aetiology of diseases are made possible the implementation of modern therapies with biological drugs, which are a heterogeneous group of substances working by modulating the body’s immune response. Currently, biological medications are used in an increasing number of indications.

Inflammatory bowel disease induced by bimekizumab

Dominika Wietrzykowska-Grishanovich 1 , Maciej Pleskacz 1 , Radosław Kempiński 2

Dominika Wietrzykowska-Grishanovich

¹

,

Maciej Pleskacz

¹

,

Radosław Kempiński

²